🧬 What Is Peptide Therapy?
Peptide therapy uses short chains of amino acids that interact with biological pathways in the body.
Depending on the molecule, a peptide may act as a hormone, receptor agonist, signaling molecule, growth-hormone releasing factor, metabolic drug, or experimental biological compound.
That broad definition is exactly why the term can be confusing.
Two treatments described by clinics as peptide therapy may have almost nothing in common clinically.
One may be a pharmaceutical product that has completed large randomized trials for a defined disease. Another may be a compound whose reputation comes mainly from animal studies, laboratory experiments, or biohacking communities.
A 2026 review in Sports Medicine highlighted this divide, describing a rapidly growing market that contains both approved peptide medicines and unapproved compounds with much thinner human safety and efficacy evidence.⁶
🔬 How Do Peptides Work in the Body?
Peptides can bind to specific receptors or influence signaling pathways involved in processes such as metabolism, appetite, hormone release, sexual function, inflammation, or tissue biology.
That does not mean peptides generally “tell your body to heal.”
Each compound needs to be evaluated independently.
A useful way to think about the evidence is:
molecule + formulation + route + dose + indication
not simply the word peptide.
🧩 Registered, Compounded, and Experimental Peptides Are Not the Same
A practical way to understand the peptides Dubai clinics may discuss is to separate them into three broad groups.
The distinction becomes particularly important when broad goals such as anti-aging, recovery, performance, or optimization are being marketed.
A peptide can have legitimate human evidence for one medical indication while having little evidence for a different longevity or performance use.
Evidence, regulatory authorization, product quality, and clinical suitability are four different questions.
⚖️ Are Peptides Legal in Dubai and the UAE?
There is no single legal status for “peptides” in Dubai.
The relevant pathway depends on the exact medical product, whether it holds Emirates Drug Establishment authorization or follows another applicable pathway, how it is manufactured or compounded, and how it is prescribed and handled by the healthcare facility.
Dubai added an important local layer in 2026.
On July 29, 2026, the Dubai Health Authority (DHA) published Circular CIR-2026-00000107: Regulations for Handling Peptide Products in Healthcare Facilities.
DHA subsequently issued a September circular inviting licensed healthcare facilities to a workshop focused on the proper regulatory handling of peptides in Dubai.¹
The existence of a dedicated peptide framework is significant because the Dubai market now spans conventional medicines, compounded preparations, and emerging compounds that can all be promoted under the same broad label.
🏛️ How Does UAE Medical-Product Regulation Apply?
Federal Decree-Law No. 38 of 2024 has been in force since January 2, 2025 and governs medical products, pharmacists, and pharmaceutical establishments across the UAE.²
As a general rule, the law restricts the commercial circulation and use of medical products without the applicable Emirates Drug Establishment approval.
It also recognizes an exemption from the ordinary marketing-authorization requirement for products prepared by licensed compounding pharmacies.²
But that exemption is not unlimited.
Article 95 places separate restrictions on pharmaceutical compounding, including limitations involving copies of already authorized products and prohibitions relevant to certain improvised, unstudied, research, or experimental preparations.²
MOHAP also maintains technical and health requirements for licensed compounding pharmacies under Ministerial Decree No. 228 of 2023.³
📋 UAE Peptide Regulatory Pathways at a Glance
This table is a decision aid, not a substitute for product-specific regulatory verification.
🧪 What Role Does the Emirates Drug Establishment Play?
The Emirates Drug Establishment, or EDE, is the federal authority responsible for regulating medical and pharmaceutical products.
Its product-classification service helps determine a product's regulatory category and whether marketing authorization is required.⁴
Its pharmaceutical marketing-authorization pathway includes requirements involving areas such as product quality, stability, supporting evidence, and pharmacovigilance.⁵
EDE also maintains a public directory of registered medical products.
That can be useful when checking a named finished medicine, although product listings should still be interpreted in the context of the exact formulation and proposed indication.
For patients, the practical lesson is simple:
Do not ask only whether “peptides are allowed.”
Ask what exact product is being proposed and under what regulatory pathway it is being used.
🔎 How Can You Verify a Peptide Product in the UAE?
Start with the exact product, not the clinic's marketing category.
You do not need to become a pharmacologist. You do need enough information to understand what is actually being administered.
A useful question to ask a clinic is:
“What exact product will I receive, and what regulatory pathway applies to that product for the treatment you are proposing?”
That question usually reveals far more than asking whether a clinic offers “legal peptides.”
🧪 Does Peptide Therapy Actually Work? What Human Evidence Shows
Some peptide medicines work for clearly defined medical indications.
Other peptides commonly marketed for longevity, recovery, or performance remain experimental.
The evidence ranges from large randomized clinical-development programs to laboratory and animal research.
A molecule can show a powerful biological effect without producing a meaningful patient outcome.
Likewise, an encouraging animal study does not establish that the same benefit occurs safely in humans.
A 2026 review of approved and unapproved peptide therapies concluded that many emerging compounds show promising biological effects while rigorous human safety and clinical-outcome data remain limited.⁶
The purpose of this table is not to rank the “best peptides.”
It is to show why peptides need to be judged individually.
🩹 BPC-157 in Dubai: Promising Science or Experimental Therapy?
BPC-157 is scientifically interesting, but its human evidence remains much weaker than its reputation in recovery and biohacking circles suggests.
It is commonly discussed for tendon injuries, ligament repair, muscle recovery, inflammation, and gastrointestinal health.
A 2025 systematic review identified 36 relevant studies.
Of those, 35 were preclinical and only one involved human clinical data. Animal studies produced encouraging findings in musculoskeletal models, but robust human safety and efficacy evidence was absent.⁷
A responsible description is therefore:
BPC-157 has substantial preclinical interest for tissue repair, but it has not been established as a proven human tendon-, ligament-, or muscle-healing therapy.
🧭 What Should You Ask if BPC-157 Is Proposed?
Ask what diagnosis is being treated, what human evidence supports that particular use, what exact product is being administered, how it was sourced, and what monitoring the physician considers appropriate.
For a compound with limited human safety evidence, uncertainty should be part of informed consent rather than hidden behind a list of potential benefits.
📈 CJC-1295 and Ipamorelin: What Do Human Studies Actually Show?
Both compounds are commonly discussed in relation to growth-hormone signaling, body composition, recovery, and anti-aging. Their human evidence needs to be interpreted more narrowly.
🔬 CJC-1295
CJC-1295 has demonstrated clear biological activity in humans, but that does not prove broad longevity, recovery, or performance benefits.
In randomized studies of healthy adults, the studied long-acting CJC-1295 compound increased mean growth hormone by approximately 2 to 10 times baseline for six days or longer and increased IGF-1 by approximately 1.5 to 3 times baseline for 9 to 11 days.⁸
That demonstrates pharmacological activity.
It does not establish that CJC-1295:
- extends lifespan,
- improves tendon healing,
- produces durable body-composition changes,
- improves athletic performance, or
- reverses biological aging.
Biological activity is not the same as demonstrated clinical benefit.
🧪 Ipamorelin
Ipamorelin can stimulate growth-hormone release in humans, but its broader wellness claims remain inadequately established.
Human pharmacokinetic research has demonstrated growth-hormone release after ipamorelin administration.⁹
A later randomized Phase II trial evaluated ipamorelin in 117 patients following bowel surgery.
Its primary efficacy endpoint was not statistically significant.¹⁰
The practical question is therefore not simply whether ipamorelin has biological effects.
It is whether human evidence supports the specific outcome being promised to you.
✅ Examples of Peptides With Stronger Human Evidence
Not every peptide discussed in longevity or wellness medicine sits at the same experimental stage.
Two useful examples show why the indication matters.
🧍 Tesamorelin
Tesamorelin has meaningful human evidence, but for a defined medical population and indication.
In a randomized placebo-controlled study involving 404 people living with HIV and excess abdominal fat, visceral adipose tissue decreased approximately 10.9% after six months with tesamorelin versus 0.6% with placebo.
Participants who continued treatment experienced further reductions over 12 months, while improvements diminished after discontinuation.¹¹
A 2026 meta-analysis of five randomized controlled trials also found reductions in visceral adipose tissue, trunk fat, hepatic fat, and waist circumference among adults with HIV-associated lipodystrophy.¹²
That is legitimate human clinical evidence.
It does not automatically establish tesamorelin as a longevity treatment for otherwise healthy adults.
❤️ Bremelanotide / PT-141
Bremelanotide also has substantial clinical evidence for a specific sexual-health indication.
Two randomized Phase III trials evaluated 1,267 premenopausal women with hypoactive sexual desire disorder.
Treatment improved sexual desire and distress associated with low desire compared with placebo, while nausea, flushing, and headache occurred more often with treatment.¹³
Again, the evidence relates to a defined patient population and clinical indication.
🧬 TB-500 vs Thymosin Beta-4: Why the Exact Molecule Matters
Human research involving full-length thymosin beta-4 should not automatically be used as evidence that TB-500 works.
For example, a randomized study involving 73 patients evaluated topical thymosin beta-4 in venous ulcers and suggested a possible wound-healing signal.¹⁴
That is clinically interesting.
TB-500, however, is a related peptide fragment commonly marketed in performance and recovery settings.
A 2026 FDA review of TB-500-related bulk substances found insufficient human administration and safety evidence to support the compounded use being evaluated.¹⁵
The broader lesson matters well beyond TB-500:
Evidence for a related molecule is not necessarily evidence for the exact product being administered.
💉 Other Emerging Peptides: GHK-Cu, Epitalon, and MOTS-c
These compounds attract considerable interest in aesthetics, longevity, and biohacking, but their evidence should be interpreted according to what has actually been studied.
🧴 GHK-Cu
GHK-Cu has an interesting regenerative and aesthetic evidence base, but findings from topical or skin-directed use cannot simply be extrapolated to systemic injections.
A 2026 systematic review identified 20 eligible studies, including 18 preclinical studies and two randomized controlled trials.
The available clinical evidence suggested potential aesthetic effects, but the authors emphasized methodological variation and the limited number of well-designed trials.¹⁶
That is very different from proving injectable GHK-Cu as a systemic anti-aging therapy.
🧫 Epitalon
Epitalon has shown telomere-related effects in laboratory cell models, not proof of longer human lifespan.
A 2025 study reported telomere-length effects after exposing cultured human cells to Epitalon. The study included normal cell lines and cancer-derived cell lines and investigated cellular mechanisms involving telomerase and alternative lengthening of telomeres.¹⁷
It did not demonstrate that Epitalon injections extend human life, prevent disease, improve healthspan, or reverse biological age.
⚡ MOTS-c
MOTS-c is scientifically interesting because of its links to mitochondrial and metabolic biology, but therapeutic use remains early.
A 2026 review described research connecting MOTS-c with metabolism, oxidative stress, inflammation, immune responses, and mitochondrial function while emphasizing the need for further translational and clinical research.¹⁸
For longevity-focused patients, this is an area worth following.
It is not yet equivalent to a clinically established longevity treatment.
💰 How Much Does Peptide Therapy Cost in Dubai?
There is no useful single average price for peptide therapy in Dubai because clinics sell very different products, consultations, and program structures.
Current provider-published examples illustrate the range:
One Dubai provider publishes compound-specific and general peptide pricing, while another publishes consultation, session, monthly-program, and advanced-program ranges.²⁰˒²¹
These are provider-published market examples, not standardized UAE prices or treatment recommendations.
Currency conversions are approximate exchange rates and will fluctuate.
💳 What Changes the Total Price?
A lower headline price is not automatically better value.
Likewise, a higher-priced longevity package is not automatically more medically sophisticated.
🩺 What Should Happen Before Starting Peptide Therapy?
A medically credible peptide protocol should begin with the patient and the treatment objective, not with a menu of compounds.
The physician should understand why you are considering treatment, what diagnosis or outcome is being targeted, your medical history, current medications, and anything that could make the proposed intervention inappropriate.
Testing should also have a clear purpose.
There is no universal “peptide blood panel” that every patient needs.
Investigations should follow logically from the molecule's mechanism, your health history, and the risks that need monitoring.
One useful question is:
“What decision will this test change?”
If the answer is unclear, the test may be adding more to the package than to the clinical decision.
The treatment objective should also be measurable.
“More vitality” is difficult to evaluate.
A defined symptom, functional measure, body-composition outcome, validated clinical endpoint, or clinically relevant biomarker gives you and your physician a clearer basis for deciding whether treatment is helping.
⚠️ What Are the Risks of Peptide Therapy?
There is no universal peptide-therapy risk profile. Safety depends on the compound, dose, formulation, route, duration, patient, and product quality.
🧪 Compound-Specific Biological Risk
A growth-hormone secretagogue raises different questions from a melanocortin-receptor drug or metabolic peptide.
That is why a generic statement such as “peptide therapy has only mild side effects” is not sufficiently informative.
💉 Peptide Injection and Administration Risk
Peptide injections in Dubai may be administered in clinics or, depending on the treatment, prepared for patient use outside the facility.
Injected therapies can introduce risks such as local reactions, infection, dosing errors, or handling problems.
The appropriate precautions depend on the product and how it is administered.
🧫 Product-Quality Risk
For compounded or non-standard preparations, identity, potency, contamination, sterility, storage, degradation, and batch traceability become particularly important.
The recent medical literature on emerging peptides specifically identifies limited safety evidence and products operating outside conventional pharmaceutical channels as potential concerns.⁶˒⁷
❓ Evidence Uncertainty
Uncertainty itself is clinically relevant.
When relatively few people have received a compound under controlled research conditions, rare adverse events, long-term effects, drug interactions, and risks in specific populations may simply be unknown.
That does not prove the treatment is unsafe.
It means the confidence of the safety claim should match the evidence available.
🧪 Research Peptides vs Clinical Peptide Treatment
A peptide sold online as “research use only” should not be treated as equivalent to a medical product supplied through a regulated clinical pathway.
This distinction matters because searches for peptides in Dubai can surface clinics, pharmacies, health information, and research-peptide vendors side by side.
Under UAE federal law, a licensed compounding pathway does not create blanket authorization for products prepared for research, development, or experimentation.²
Likewise, personal import rules for travelers should not be confused with authorization for a clinic to commercially supply or administer the same product.
For patients, the practical distinction is straightforward:
Commercial availability does not establish clinical legitimacy.
A website shipping a vial is not equivalent to a physician prescribing a clearly identified product through an appropriate clinical and regulatory pathway.
🧭 The STEMCIERGE Peptide Protocol Verification Framework
Before committing to an expensive peptide program, you should be able to get clear answers to the following questions.
The goal is not to make patients become pharmaceutical experts.
It is to make the treatment transparent enough that an informed decision is possible.
🏥 How Do You Evaluate a Peptide Clinic in Dubai?
A licensed clinic is the starting point, not the entire due-diligence process.
Facility licensing is important, but it does not by itself establish that every peptide, formulation, indication, combination, or advertising claim offered by that provider is equally well supported.
A more useful evaluation looks at the entire treatment chain:
physician → indication → product → regulatory pathway → evidence → monitoring
A credible provider should be comfortable explaining what it intends to prescribe and why.
Be cautious when the conversation begins with a pre-built “longevity stack” before anyone has meaningfully reviewed your health history, medications, diagnosis, or treatment goals.
Likewise, phrases such as medical grade, pharmaceutical grade, DHA compliant, regenerative peptide, or anti-aging peptide can sound reassuring without answering the most important questions.
Ask what those terms mean for the exact product you will receive.
🏅 Competitive Athletes: Are Peptides Allowed Under WADA Rules?
Several peptides marketed for recovery, body composition, or hormonal optimization are prohibited for athletes subject to anti-doping rules.
The 2026 World Anti-Doping Agency Prohibited List includes growth-hormone releasing factors such as CJC-1295, sermorelin, and tesamorelin; growth-hormone secretagogues including ipamorelin; and thymosin-beta-4 derivatives including TB-500. BPC-157 is captured under the category for non-approved substances.¹⁹
If you compete in a tested sport, a clinic prescription does not automatically make a prohibited substance permissible.
Check the current WADA rules and your sport's Therapeutic Use Exemption requirements before beginning treatment.
🧬 Peptide Therapy vs Stem Cell Therapy in Dubai
Peptide therapy and stem cell therapy are different treatment categories and should not be evaluated using the same scientific or regulatory framework.
Some Dubai longevity clinics offer both under the same broader regenerative or optimization umbrella, but the clinical questions are very different.
🔗 Read more → Stem Cell Therapy in Dubai (Complete Guide): Costs, Regulations & Treatments
🧠 Where Does Peptide Therapy Fit Within Longevity Medicine?
Peptides may be one component of a longevity program, but they should not replace interventions with much stronger evidence for healthspan.
Dubai's longevity market increasingly combines advanced diagnostics, metabolic medicine, hormone evaluation, NAD-related interventions, regenerative therapies, exercise, nutrition, recovery technologies, and anti-aging peptides.
That creates interesting possibilities.
It can also create an incentive to start with what is newest rather than what matters most.
For most people, the foundations of healthy aging still include cardiovascular-risk management, metabolic health, exercise, sleep, nutrition, smoking avoidance, preventive screening, and appropriate treatment of diagnosed disease.
An experimental longevity peptide therefore needs to answer a demanding question:
What meaningful outcome are we expecting this intervention to add after the fundamentals are addressed?
That framework is more useful than assuming the newest therapy is automatically the most advanced.
🔗 Read more → Longevity Medicine in Dubai: Treatments, Costs, Evidence & How to Choose a Program
✔️ Questions to Ask Before Starting Peptide Therapy in Dubai
Before paying for treatment, you should be able to get clear answers to these questions:
- What exact peptide and product are you proposing?
- Why is it being recommended for my specific objective or diagnosis?
- What human evidence supports this particular use?
- What regulatory pathway applies to the product in the UAE?
- Who manufactures or compounds it?
- How is the product sourced, stored, and traced?
- What risks are known for this exact compound?
- What important risks or long-term effects remain uncertain?
- Which tests or monitoring are clinically necessary?
- How will we decide whether the treatment is working?
- What would cause the physician to change or stop the protocol?
- What is the complete cost, including follow-up and testing?
- What alternatives have stronger evidence for the same goal?
If those answers remain vague after a medical consultation, that uncertainty is useful information.
A good provider should make the decision easier to understand, not harder.
❓ Frequently Asked Questions
Is BPC-157 legal in Dubai?
BPC-157's status should not be inferred simply from clinic availability or online sales. Ask for the exact product, formulation, source, intended use, and applicable UAE regulatory pathway. DHA's 2026 peptide framework and federal medical-product rules make product-specific verification more useful than a blanket statement about whether “BPC-157 is legal.”¹˒²
Does FDA approval matter for peptide treatment in Dubai?
FDA approval can be useful when understanding a product's evidence and international regulatory history, but U.S. approval does not establish UAE authorization. For treatment in Dubai, the relevant EDE and DHA requirements still need to be considered.⁴˒⁵
Can you buy peptides online in Dubai?
Online availability does not establish that a product is authorized, safe, or appropriate for human treatment. Research products and clinical medicines follow different pathways, and a commercially available vial should not be treated as equivalent to a physician-prescribed product supplied through a regulated healthcare pathway.
Are peptides good for anti-aging?
There is no evidence supporting “peptide therapy” as one proven general anti-aging treatment. Some peptide medicines have evidence for specific clinical effects, while compounds promoted specifically for longevity frequently have much thinner human outcome data.
How long does peptide therapy take to work?
There is no universal timeline. It depends on the molecule, indication, route, dose, endpoint, and treatment duration. A generic results timeline applied to very different peptides should be interpreted cautiously.
🧪 Peptide Therapy in Dubai: The Bottom Line
Peptide therapy in Dubai is neither one miracle treatment nor one experimental category.
It covers a spectrum ranging from medicines supported by substantial human clinical trials to emerging compounds whose commercial reputation currently runs well ahead of their evidence.
The most useful question is therefore not:
“Are peptides good?”
It is:
What exact compound, product, indication, regulatory pathway, evidence base, and monitoring plan am I being offered?
Dubai's new 2026 peptide framework makes that level of specificity particularly relevant.
For patients exploring longevity, recovery, metabolic health, performance, or regenerative medicine, the goal does not have to be rejecting innovation.
It is learning how to distinguish a promising scientific idea from an established medical treatment, and knowing enough to ask better questions before making an expensive health decision.
🔬 How STEMCIERGE Researched This Guide
STEMCIERGE created this guide to help patients distinguish established medical evidence from emerging research, regulatory status from commercial availability, and scientific findings from treatment marketing.
Our research prioritized primary and authoritative sources, including Dubai Health Authority guidance, UAE federal legislation, Emirates Drug Establishment resources, peer-reviewed clinical trials, systematic reviews, current regulatory publications, and recognized international medical and anti-doping authorities.
When evaluating individual peptides, we considered the exact compound, studied indication, route of administration, patient population, and strength of human evidence rather than assuming that findings for one molecule or use apply to another.
Published clinic information was used where helpful to understand current Dubai treatment offerings and publicly advertised pricing, but provider marketing claims were not treated as evidence of safety or effectiveness.
Where evidence is early, conflicting, primarily preclinical, or unavailable for a particular use, we aim to state that clearly rather than imply greater certainty than the research supports.
🔖 Medical Disclaimer
This guide is for educational and informational purposes only and does not constitute medical advice, diagnosis, treatment recommendation, or an endorsement of any specific peptide, clinic, physician, product, or protocol.
Peptide therapies can differ substantially in their evidence, regulatory status, formulation, quality, risks, and suitability for individual patients. Some compounds discussed in this guide may be investigational, used outside established indications, supported by limited human evidence, or unsuitable for certain individuals.
Regulations and product registrations may also change. Before undergoing treatment, discuss your medical history, medications, diagnosis, and goals with an appropriately licensed physician and independently verify the status of the exact product and protocol being proposed with the relevant UAE regulatory authorities where appropriate.
Competitive athletes should additionally confirm current anti-doping requirements, as some peptide substances may be prohibited under WADA or sport-specific rules.
STEMCIERGE does not provide medical diagnosis or prescribe treatment.
📚 References
1. Dubai Health Authority. Regulations for Handling Peptide Products in Healthcare Facilities, Circular CIR-2026-00000107, July 29, 2026; related DHA peptide-regulation workshop circular CIR-2026-00000167, September 2026.
2. United Arab Emirates. Federal Decree-Law No. 38 of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments. Effective January 2, 2025. See particularly Articles 5 and 95 regarding marketing authorization and pharmaceutical compounding.
3. UAE Ministry of Health and Prevention. Ministerial Decree No. 228 of 2023 Regarding the Technical and Health Requirements for Compounding Pharmacies.
4. Emirates Drug Establishment. Classification of a Product. EDE regulatory classification service.
5. Emirates Drug Establishment. Issuance of Marketing Authorization for a Drug or Biopharmaceutical Product.
6. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026;56(8):1921–1935. DOI: 10.1007/s40279-026-02437-0. (PubMed)
7. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. PMID: 40756949.
8. Teichman SL, et al. Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. PMID: 16352683.
9. Gobburu JV, et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412–1416. PMID: 10496658.
10. Beck DE, et al. Prospective, Randomized, Controlled, Proof-of-Concept Study of Ipamorelin for Postoperative Ileus. International Journal of Colorectal Disease. 2014;29(12):1527–1534. PMID: 25331030.
11. Falutz J, et al. Effects of Tesamorelin in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311–322. PMID: 20101189.
12. Badran AS, Helal A, Shata KS, Ayesh H. Body Composition, Hepatic Fat, Metabolic, and Safety Outcomes of Tesamorelin, a GHRH Analogue, in HIV-Associated Lipodystrophy: A Meta-Analysis of Randomized Controlled Trials. Obesity Research & Clinical Practice. 2026;20(1):2–12. DOI: 10.1016/j.orcp.2026.01.002. (PubMed)
13. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899–908. PMID: 31599840.
14. Guarnera G, et al. The Effect of Thymosin Treatment of Venous Ulcers. Annals of the New York Academy of Sciences. 2010;1194:207–212. PMID: 20536470.
15. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee materials addressing TB-500 and peptide bulk substances, July 2026.
16. Mokhtar J, Mohamad B, Haddad J, Said A, Menon A, Kreutz-Rodrigues L, Vyas KS, Cetrulo CL Jr, Lellouch AG. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthetic Surgery Journal. Published August 20, 2026. DOI: 10.1093/asj/sjag169. (PubMed)
17. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon Increases Telomere Length in Human Cell Lines Through Telomerase Upregulation or ALT Activity. Biogerontology. 2025;26(5):178. DOI: 10.1007/s10522-025-10315-x. (PubMed)
18. Amado CA, Agüero J, García-Unzueta M, Berja A, Lavín BA, Martín-Audera P. MOTS-c: How a Secreted Mitochondrial Microprotein May Become a Potential Treatment for Inflammatory Lung Diseases. Journal of Translational Medicine. 2026;24(1):1031. DOI: 10.1186/s12967-026-08398-2. (PubMed)
19. World Anti-Doping Agency. The 2026 Prohibited List. Effective January 1, 2026.
20. Enfield Royal Clinic. Publicly advertised peptide-therapy pricing in Dubai, accessed September 2026. Used for market-pricing context only, not as medical evidence.
21. Novomed. Publicly advertised peptide-therapy pricing in Dubai, accessed September 2026. Used for market-pricing context only, not as medical evidence.
